Transepithelial Accelerated Corneal Collagen Cross-Linking: Two-Year Results

• Tipo: Artigo em Revista Científica Internacional
• Data: 2020

Autores

Ana Cunha (Autor) FMUP; Sardinha, T (Autor) Outra; Torrao, L (Autor) Outra; Moreira, R (Autor) Outra; Falcão-Reis F (Autor) FMUP; Pinheiro Costa, J (Autor) Outra

Revista

Título: Clinical Ophthalmology

Vol. 14

Páginas: 2329-2337

ISSN: 1177-5467

Editora: Dove Medical Press

Indexação

ISI Web of Knowledge - 2 Citações

Scopus - 2 Citações

Outras Informações

ID Authenticus: P-00S-MTR

DOI: 10.2147/opth.s252940

Abstract (EN): Purpose: To report 2-year outcomes of trans-epithelial accelerated corneal collagen crosslinking (TE-ACXL) procedure in the treatment of progressive keratoconus patients. Patients and Methods: Twenty-four eyes from 24 patients who underwent TE-ACXL (6mW/cm2 for 15 minutes) were included in this retrospective interventional study. Bestcorrected visual acuity (BCVA), keratometry values, thinnest corneal thickness (PachyMin) and topometric indexes were analysed preoperatively and at 6-month, 12-month, 18-month and 24-month postoperative. Progression was assessed by increase >= 1.00D in maximum keratometry (Kmax); increase >= 1.00D in corneal astigmatism; decrease >= 2% in PachyMin; increase >= 0.42 in D-index. Results: There were no complications during or after TE-ACXL. No significant differences (Delta) were observed between baseline and 12-month or 24-month postoperative: Delta BCVA (-0.08 +/- 0.25, p=0.190; -0.04 +/- 0.17, p=0.588), Delta Kmax (-0.08 +/- 1.32, p=0.792; -1.04 +/- 1.89, p=0.135), Delta Astigmatism (-0.15 +/- 0.89, p=0.485; -0.24 +/- 1.38, p=0.609), Delta PachyMin (-0.56 +/- 15.70, p=0.882; 0.56 +/- 18.74, p=0.931), Delta Index Surface Variation (Delta ISV) (-2.11 +/- 10.27, p=0.395; -4.67 +/- 17.32, p=0.442), Delta Index Vertical Asymmetry (Delta IVA) (-0.05 +/- 0.17, p=0.208; -0.08 +/- 0.26, p=0.397),.Index Height Decentration (Delta IHD) (0.00 +/- 0.02, p=0.368; -0.01 +/- 0.04, p=0.484), Delta KI (0.00 +/- 0.05, p=0.851; 0.01 +/- 0.06, p=0.877) and Delta D-index (0.15 +/- 1.14, p=0.572; 0.06 +/- 1.36, p=0.892). Eleven to 33% of patients had disease progression at 24-month postoperative according to the parameters used to determine progression. Conclusion: Although some patients maintain disease progression, TE-ACXL seems to be a safe and effective treatment for keratoconus over the 2-year follow-up period. Studies with longer follow-up periods and larger patient cohorts are recommended.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 9